Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
2019 · Nature Communications · 383 citations
https://doi.org/10.1038/s41467-019-09068-2
A
Alberto Servetto
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
165
Papers
2.2K
Citations
23
h-index
37
i10-index
Alberto Servetto is an academic researcher from Federico II University Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Advanced Breast Cancer Therapies & Lung Cancer Treatments and Mutations. The author has an h-index of 23, co-authored 141 publications.
ORCID: 0000-0003-3624-224XPapers by this author
worksHedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
2017 · British Journal of Cancer · 95 citations
https://doi.org/10.1038/bjc.2017.116
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
2021 · Cancer Cell · 94 citations
https://doi.org/10.1016/j.ccell.2021.06.001
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
2014 · British Journal of Cancer · 86 citations
https://doi.org/10.1038/bjc.2014.241
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
2020 · Cancer Cell · 49 citations
https://doi.org/10.1016/j.ccell.2019.12.013
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
2024 · Cancer Letters · 23 citations
https://doi.org/10.1016/j.canlet.2024.216968
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat